Vivus, Inc.

VIVUS, Inc., founded in 1991, is developing and commercializing advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. The company's core technology, the transurethral system for erection, is based on the discovery that the urethra, although an excretory duct, can absorb certain pharmacologic agents into the surrounding erectile tissues. MUSEŽ (alprostadil) is now available by prescription throughout the United States. VIVUS filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) for its first product, MUSE(alprostadil) urethral suppository for consideration on March 27, 1996. MUSE received priority review status by the FDA and was cleared for marketing on November 19, 1996. VIVUS' first product contains alprostadil, the generic name for the synthetic version of prostaglandin E1, a naturally-occurring blood vessel dilator. Alprostadil was approved by the FDA for the treatment of erectile dysfunction via needle injection into the penis in 1995, and has been prescribed in the United States since 1981 for preoperative management of newborns with congenital heart defects.

Activity:

- Manufacturing

Product / Technology type(s) covered:

- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: